ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mastella, G
Right arrow Articles by McKenzie, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mastella, G
Right arrow Articles by McKenzie, S.
Eur Respir J 2000; 16: 464-471
Copyright © ERS Journals Ltd 2000


Original Articles

Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis

G Mastella, M Rainisio, HK Harms, ME Hodson, C Koch, J Navarro, B Strandvik, and SG McKenzie

Allergic bronchopulmonary aspergillosis (ABPA) is a disease resulting from a hypersensitivity response to Aspergillus fumigatus, although the pathogenesis of the disease is unknown and its prevalence in cystic fibrosis (CF) is still poorly defined. Data from the Epidemiologic Registry of Cystic Fibrosis (ERCF) on 12,447 CF patients gathered from 224 CF centres in nine European countries were analysed. The ERCF definition of ABPA diagnosis is a positive skin test and serum precipitins to A. fumigatus, together with serum immunoglobulin (Ig)E levels >1,000 U x mL(-1) and additional clinical or laboratory parameters. The overall prevalence of ABPA in the ERCF population was 7.8% (range: 2.1% in Sweden to 13.6% in Belgium). Prevalence was low <6 yrs of age but was almost constant approximately 10% thereafter. No sex differences were observed. ABPA affected 8.0% of patients with a deltaF508/deltaF508 genotype and 5-6% with deltaF508/G551D, deltaF508/G542X and deltaF508/N1303K genotypes. ABPA patients presented a lower forced expiratory volume in one second (FEV1) than those without ABPA at any age and the prevalence ranged from 6.6% in patients with FEV1 > or =20-12.9% in those with FEV1 <40%. ABPA was associated with higher rates of microbial colonization, pneumothorax and massive haemoptysis, and with higher IgG serum levels and poorer nutritional status. A mixed model regression analysis of lung function showed that FEVI decline during the follow-up period was not substantially different in ABPA patients compared with non-ABPA patients for any subgroups based on age or disease severity at enrollment. To conclude, allergic bronchopulmonary aspergillosis is a frequent complication in cystic fibrosis patients, particularly after the age of 6 yrs, and it is generally associated with a poorer clinical condition. However, any clear independent influence of allergic bronchopulmonary aspergillosis on the rate of lung function decline in the short term was not shown.


This article has been cited by other articles:


Home page
JRSMHome page
M. F Thomas
Life-threatening allergic bronchopulomnary aspergillosis treated with methylprednisolone and anti-IgE monoclonal antibody
J R Soc Med, July 1, 2009; 102(Supplement_1): 49 - 53.
[Full Text] [PDF]


Home page
ChestHome page
R. Agarwal
Allergic Bronchopulmonary Aspergillosis
Chest, March 1, 2009; 135(3): 805 - 826.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P. Latzin, D. Hartl, N. Regamey, U. Frey, M. H. Schoeni, and C. Casaulta
Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
Eur. Respir. J., January 1, 2008; 31(1): 36 - 42.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Kraemer, N. Delosea, P. Ballinari, S. Gallati, and R. Crameri
Effect of Allergic Bronchopulmonary Aspergillosis on Lung Function in Children with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1211 - 1220.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. B. Allard, M. E. Poynter, K. A. Marr, L. Cohn, M. Rincon, and L. A. Whittaker
Aspergillus fumigatus Generates an Enhanced Th2-Biased Immune Response in Mice with Defective Cystic Fibrosis Transmembrane Conductance Regulator
J. Immunol., October 15, 2006; 177(8): 5186 - 5194.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
H. Kunst, M. Wickremasinghe, A. Wells, and R. Wilson
Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis
Eur. Respir. J., August 1, 2006; 28(2): 352 - 357.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. Shoseyov, K. G. Brownlee, S. P. Conway, and E. Kerem
Aspergillus bronchitis in cystic fibrosis.
Chest, July 1, 2006; 130(1): 222 - 226.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
S. P. Conway, C. Etherington, D. G. Peckham, K. G. Brownlee, A. Whitehead, and H. Cunliffe
Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis
J. Antimicrob. Chemother., May 1, 2004; 53(5): 841 - 847.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
I M Balfour-Lynn, U Mohan, A Bush, and M Rosenthal
Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children
Arch. Dis. Child., April 1, 2004; 89(4): 315 - 319.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
L. Saiman and J. Siegel
Infection Control in Cystic Fibrosis
Clin. Microbiol. Rev., January 1, 2004; 17(1): 57 - 71.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
H Witt
Chronic pancreatitis and cystic fibrosis
Gut, May 1, 2003; 52(90002): ii31 - 41.
[Abstract] [Full Text]


Home page
ChestHome page
M. Helmi, R. B. Love, D. Welter, R. D. Cornwell, and K. C. Meyer
Aspergillus Infection in Lung Transplant Recipients With Cystic Fibrosis: Risk Factors and Outcomes Comparison to Other Types of Transplant Recipients
Chest, March 1, 2003; 123(3): 800 - 808.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
I M Balfour-Lynn and J S Elborn
"CF asthma": what is it and what do we do about it?
Thorax, August 1, 2002; 57(8): 742 - 748.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Skov, K.M. Main, I.B. Sillesen, J. Muller, C. Koch, and S. Lanng
Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide
Eur. Respir. J., July 1, 2002; 20(1): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. H. Nikolaizik, M. Weichel, K. Blaser, and R. Crameri
Intracutaneous Tests with Recombinant Allergens in Cystic Fibrosis Patients with Allergic Bronchopulmonary Aspergillosis and Aspergillus Allergy
Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 916 - 921.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
L. Maiz, M. Cuevas, S. Quirce, J. F. Canon, A. Pacheco, A. Sousa, and H. Escobar
Serologic IgE Immune Responses Against Aspergillus fumigatus and Candida albicans in Patients With Cystic Fibrosis
Chest, March 1, 2002; 121(3): 782 - 788.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Navarro, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, G. Mastella, B. Strandvik, and S.G. McKenzie
Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF
Eur. Respir. J., August 1, 2001; 18(2): 298 - 305.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, B. Strandvik, and S.G. McKenzie
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Eur. Respir. J., May 1, 2001; 17(5): 1052 - 1053.
[Full Text] [PDF]


Home page
Eur Respir JHome page
J.A. Kastelik, I. Aziz, A.E. Redington, and A.H. Morice
Allergic bronchopulmonary aspergillosis in cystic fibrosis
Eur. Respir. J., January 1, 2001; 17(1): 156 - 156.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.